A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
{{output}}
Introduction: Bispecific antibodies (BsAbs) are novel immunotherapy agents for the treatment of relapsed/refractory multiple myeloma (RRMM). Currently, 3 BsAbs (teclistamab, talquetamab, and elranatamab) are approved for the trea... ...
